Last reviewed · How we verify
NCT07345143
Artificial Intelligence and Gestacional Diabetes
NA trial testing monitoring model for women with gestacional diabetes using pharmacological therapy in Gestational Diabetes in 100 participants. Enrolling by invitation.
20 December 2026
Quick facts
| Lead sponsor | JOSE FERNANDO VILELA-MARTIN |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 June 2024 |
| Primary completion | 20 December 2026 |
| Estimated completion | 20 December 2027 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- monitoring model for women with gestacional diabetes using pharmacological therapy
Conditions studied
- Gestational Diabetes — all drugs for Gestational Diabetes →
- Macrosomia, Fetal — all drugs for Macrosomia, Fetal →
Sponsor
JOSE FERNANDO VILELA-MARTIN
Who can join
Adults 18 to 40, female only, with Gestational Diabetes or Macrosomia, Fetal. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Artificial intelligence (AI) technology can assist medical teams in remote monitoring and continuing education of women with gestational diabetes (GDM), potentially improving adherence to interventions and impacting outcomes. An AI remote monitoring model called "monitoring model for women with GDM using pharmacological therapy," created by the ChamouDr technical team, will be analyzed focusing on disease education, glycemic control monitoring, and therapeutic interventions. Women diagnosed with GDM are invited to participate in the study and sign a free and informed consent form. The AI tool is installed on the pregnant woman's cell phone, who receives instructions to collect capillary blood glucose 6 times a day according to the protocol, at home, and report the results via WhatsApp to the study tool. Algorithm generated by the AI model based on self monitoring of blood glucose (SMBG) informs about diabetes control in the last week. The dashboard is accessible via a web browser, and signals: in green and red for patients with satisfactory and unsatisfactory control, respectively. Thus, the AI model optimizes the team's time in analyzing and treating patients appropriately in a simple, cost-effective, and accessible way.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07345143
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gestational Diabetes
Currently open trials in the same condition.
- NCT07171684 — Single vs Multi-Dose Insulin for Glycemic Control (SUGAR) · NA · recruiting
- NCT07314944 — Maternal Sleep and Lifestyle, Metabolic Health, and Perinatal Outcomes in Gestational Diabetes · recruiting
- NCT06571487 — Growth Hormone Resistance of Beta-cells · recruiting
- NCT07336914 — Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes · NA · recruiting
- NCT07174245 — Pregnancy and Postpartum CGM in GDM · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07345143 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by JOSE FERNANDO VILELA-MARTIN
- Last refreshed: 15 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07345143.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing